Sells branded pharmaceutical formulations in the Indian market through a field force of 3,100 medical representatives who visit doctors, supported by chronic and semi-chronic therapy focus that contributed 72% of FY26 revenue. The portfolio includes two brands above INR 100 crore in annual sales and eight brands in the INR 50-100 crore band; therapy mix spans women's health (ranked 5th in Gynaecology), with newer entries in biosimilars (Fostine R, Wyntide, Tyvenza) and Semaglutide for diabetes/obesity. Two acquisitions completed in FY26 — Wokadine (Povidone Iodine, #2 in that segment) for INR 20 crore and a 7-brand portfolio from Bayer Zydus — are being scaled as separate revenue lines. Manufacturing happens at an EU-GMP certified Bhayla, Ahmedabad facility, where a new women's hormone plant (194 million tablets/capsules and 1.5 million ointments/gels per year) commenced commercial production in June 2026, and the company has EAEU GMP clearance to sell into Eurasian markets. The biggest cost line is its field force and staff, with employees at 28.7% of FY26 revenue; raw materials are only 7.4% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Domestic formulations (IPM), Chronic and semi-chronic therapies (72%), Acquired brands (Wokadine, Bayer Zydus portfolio), International business. Asset-light branded formulations company with heavy field-force intensity, focused on chronic therapy and women's health.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 1,403 |
| EBITDA (ex other income) | 275 |
| margin % | 19.6 |
| Owners' profit | 185 |
| EPS, as reported (₹) | 30.27 |
| ROE % · ROCE % | 24.8 · 29.3 |
| Debt / equity (x) | 0.19 |
| Cash from operations | 229 |
| Capex | (174) |
| ₹ crore | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Revenue | 361 | 342 | 353 | 422 |
| Profit before tax | 70 | 55 | 55 | 80 |
| Net profit | 52 | 41 | 45 | 60 |
| EPS (₹) | 8.55 | 6.75 | 7.41 | 9.83 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Corona Remedies replies to BSE query on volume movement | compliance | minimal | — | — |
| 10 Sept 2026 · BSE seeks clarification on Corona Remedies volume movement | compliance | low | — | — |
| 9 Sept 2026 · NSE queries unusual volume; company says rise is market-driven, no undisclosed info | regulatory legal | medium | — | — |
| 9 Sept 2026 · NSE seeks clarification on sudden jump in trading volume | regulatory legal | medium | — | — |
| 20 Aug 2026 · Corona Remedies to attend Phillip Capital investor conference on Aug 26 | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Q1 FY27 earnings: revenue up 21.9%, beats guidance; PAT grows 30% | investor communications | medium | — | — |
| 10 Aug 2026 · Corona Remedies to attend two investor conferences in Mumbai | board shareholder meetings | low | — | — |
| 7 Aug 2026 · Q1 FY27 results: Revenue up 22%, PAT up 30% YoY | results | high | — | — |
| 3 Aug 2026 · Q1 FY27 Earnings Call Audio Recording Available on Website | investor communications | low | — | — |
| 1 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| DR. REDDY S LABORATORIES |
| 97,319 |
| 30.1 |
| 2.55 |
| 13.1 |
| 10.9 |
| 13.0 |
| 12.1 |
| 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 68.5 | 28.9 | 144 of 169 | 15% |
| P/B | 18.2 | 3.3 | 157 of 163 | 4% |
| ROCE | 28.5 | 10.8 | 11 of 183 | 95% |
| ROE | 24.8 | 10.4 | 13 of 171 | 93% |
| Debt / Equity | 0.2 | 0.1 | 97 of 171 | 44% |
| EBITDA margin | 22.8 | 17.5 | 64 of 165 | 62% |
| Market cap | 13626 | 839 | 40 of 182 | 79% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
